RapidAI Stock

RapidAI empowers clinicians to make accurate diagnostic and treatment decisions for stroke and aneurysm patients.

Sign up today and learn more about RapidAI Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About RapidAI Stock

RapidAI empowers clinicians to make accurate diagnostic and treatment decisions for stroke and aneurysm patients. RapidAI's platform uses artificial intelligence to create advanced images from non-contrast CT, CT Angiography, CT perfusion, and MRI diffusion and perfusion scans.

Funding History

September 2020$25.0M
July 2023$75.0M

Management

Co-Founder, Scientfic Lead and Board Member

Gregory Albers

CEO

Don Listwin

Senior Director of Clinical Product Development

Haithem Babiker

SVP of Engineering

Krates Ng

Chief Innovation and Technology Officer

Amit Phadnis

Director of Design

Kevin Coffey

Chief Operating Officer

John Mcgovern

CEO

Karim Karti

Senior Software Engineer

Tyson Daugherty

Country Manager

Michalina Ryn

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo